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ABSTRACT
Background Prion diseases are universally fatal and
often rapidly progressive neurodegenerative diseases.
EEG has long been used in the diagnosis of sporadic
Creutzfeldt-Jakob disease; however, the characteristic
waveforms do not occur in all types of prion diseases.
Here, we re-evaluate the utility of EEG by focusing on
the development of biomarkers. We test whether
abnormal quantitative EEG parameters can be used to
measure disease progression in prion diseases or predict
disease onset in healthy individuals at risk of disease.
Methods In the National Prion Monitoring Cohort
study, we did quantitative encephalography on 301
occasions in 29 healthy controls and 67 patients with
prion disease. The patients had either inherited prion
disease or sporadic Creutzfeldt-Jakob disease. We
computed the main background frequency, the α and θ
power and the α/θ power ratio, then averaged these
within 5 electrode groups. These measurements were
then compared among participant groups and correlated
with functional and cognitive scores cross-sectionally and
longitudinally.
Results We found lower main background frequency, α
power and α/θ power ratio and higher θ power in
patients compared to control participants. The main
background frequency, the power in the α band and the
α/θ power ratio also differed in a consistent way among
the patient groups. Moreover, the main background
frequency and the α/θ power ratio correlated
signiﬁcantly with functional and cognitive scores.
Longitudinally, change in these parameters also showed
signiﬁcant correlation with the change in clinical and
cognitive scores.
Conclusions Our ﬁndings support the use of
quantitative EEG to follow the progression of prion
disease, with potential to help evaluate the treatment
effects in future clinical-trials.
INTRODUCTION
Prion diseases are fatal, progressive, neurodegenera-
tive diseases caused by accumulation of an abnor-
mal isoform of the cellular prion protein in and
around neurons leading to synaptic dysfunction
and eventual neuronal loss.1 The most common
type is sporadic Creutzfeldt-Jakob disease (sCJD)
which accounts for ∼85% of the annual incidence
of prion disease. There are strong genetic suscepti-
bility factors in prion disease, with ∼15% of cases
being an inherited disease, all caused by mutation
of the prion protein gene (PRNP).2 A small propor-
tion is acquired, caused by the transmission of
prions during blood transfusion, neurosurgery, via
pituitary-derived growth hormone therapy or inges-
tion of bovine spongiform encephalopathy-
contaminated food products.1
Based on well-established epidemiological cri-
teria, the diagnosis of sCJD is termed ‘possible’ if
the patient has progressive dementia with <2 years
duration accompanied with at least two of the fol-
lowing clinical features: myoclonus, visual or cere-
bellar disturbance, pyramidal or extrapyramidal
dysfunction and akinetic mutism. EEG recording
can increase the conﬁdence of the diagnosis from
‘possible’ to ‘probable’ sCJD if generalised triphasic
periodic sharp wave complexes (PSWCs) are
demonstrated. PSWCs have been reported in many
studies;3–6 they appear relatively late after symptom
onset and are usually accompanied by movement
disorders (eg, myoclonus, dyskinesia and startle)
and reduced responsiveness to stimuli (akinetic
mutism or coma).7 8 Moreover, PSWCs are not
equally present in the different subtypes of sCJD.9
Other biomarkers are available for the diagnosis of
prion disease, notably signal change in the basal
ganglia, thalamus and cortex on diffusion-weighted
MRI, and assays of abnormal prion protein or its
seeding activity in tissue or bioﬂuids.10–13
Several experimental therapeutics have shown
promise in animal prion diseases and are being
developed with a view to human studies.14–16
Therefore there is an unmet need for biomarkers,
which have utility for experimental medicine:
those, which provide objective evidence of disease
progression in symptomatic patients, and which
predict clinical onset in individuals at-risk of
disease because they have been exposed to prions
or carry a PRNP mutation.
A potentially relevant approach is quantitative
EEG (qEEG) analysis. This extends the pure visual
inspection of the EEG recordings with more
precise and objective measurements. They might
therefore allow the clinician to detect subtle
changes in the EEG much before they would be
visible to the naked eye and before PSWCs appear.
qEEG techniques are more sensitive markers of the
progression in other diseases and can show stronger
correlation with the clinical signs.17 18
Here, for the ﬁrst time, we applied qEEG ana-
lysis cross-sectionally and longitudinally in 67
patients with or at-risk of prion disease in the
context of a national prospective observational
cohort study, and compared them to healthy con-
trols. Our aim was to evaluate the potential of
qEEG in prion disease as an objective biomarker of
(1) disease progression and (2) prediction of disease
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onset in healthy individuals. To this end, we automatically and
quantitatively characterised the EEG changes before the occur-
rence of the typical PSWCs and correlated these measurements
with newly developed functional measures (MRC Prion Disease
Rating Scale) and cognitive function (Mini Mental State
Examination (MMSE)) of the patients. Having repeated record-
ings from patients, we also evaluated a correlation between
change in qEEG parameters and change in functional and cogni-
tive abilities.
MATERIALS AND METHODS
Participants
Participants were recruited to the National Prion Monitoring
Cohort (2008–2013).19 This study aims to collect longitudinal,
prospective, systematic, clinical history and examination, rating
scale and functional data from patients with prion disease and
their relatives who have increased risk of developing the disease.
A key achievement of the Cohort study to date is the develop-
ment of a bespoke functionally orientated rating scale (the MRC
Prion Disease Rating Scale, subsequently termed the MRC
Scale). We selected those participants who had an EEG recorded
at the National Hospital for Neurology and Neurosurgery
(NHNN). The criteria for exclusion were that the whole EEG
recording was degraded by artefacts (leaving <40 artefact-free
epochs) or had a very small amplitude signal. The number of
participants excluded from the analysis is shown in table 1.
Ninety-six participants had EEG of suitable quality at the
NHNN. Twenty-nine participants were healthy controls, and 67
had or were at-risk of prion disease. The demographic details of
the participants are shown in table 1. For the purpose of this
study, the patient group was divided into three disease groups,
containing the participants with inherited prion disease (IPD)
with motor or cognitive deﬁcits (symptomatic IPD or sIPD),
those that not yet have any symptoms of IPD (asymptomatic or
aIPD) and those with sCJD. All IPD patients had a diagnosis
conﬁrmed by molecular genetic testing of the PRNP. The sCJD
patients all fulﬁlled epidemiological criteria for probable CJD in
life, and 13 cases were conﬁrmed by postmortem examination.
At PRNP codon 129, two sCJD patients were methionine homo-
zygous, three were valine homozygous and nine were heterozy-
gous. The aIPD participants did not have any identiﬁable
symptoms of prion disease during the data collection. The
prevalence of the different mutations in the IPD groups were as
follows—asymptomatic IPD: P102L:11, A117V:1, E200K:6,
D178N:2, 5OPRI:1; 6OPRI:2; symptomatic IPD: P102L:10,
A117V:3, E200K:1, D178N:2, 5OPRI:4; 6OPRI:5, Y163X:3,
Q212P:1, E196K:1. Three of the 30 sIPD patients were
asymptomatic at the time of recruitment and developed symp-
toms of the disease during the follow-up period. Informed
consent was obtained from each participant or from their rela-
tives according to the provisions of the Mental Capacity Act
2005. Ethical approval was obtained from the Scotland A
Research Ethics Committee.
EEG recording and analysis
EEGs were recorded in the EEG laboratory of the NHNN accord-
ing to the International Federation of Clinical Physiology guide-
lines (http://www.clinph-journal.com/content/guidelinesIFCN, last
accessed 8 February 2015), using a 19-channel Nicolet EEG
system with Ag/AgCl surface electrodes. The impedance was kept
below 5 kΩ and sampling rate was 256 Hz. The electrodes were
placed according to the international 10–20 system. The refer-
ence was placed close to electrode Pz. Each recording session
lasted for ∼20 min. The data using the common reference were
then inspected, and eye movements and high-frequency artefacts
were manually removed. Similarly, parts of the recording
showing sleep I or II stage were removed.
Further analyses were performed using the EEGLAB
(eeglab12_0_2_1b) toolbox of Matlab (MathWorks, USA). Data
were divided into 3 s epochs and bandpass ﬁltered using Finite
Impulse Response (FIR) between 1 and 25 Hz. Epochs contain-
ing artefacts were removed. Artefact rejection was partly manual
(based on visual inspection) and automatic (based on threshold-
ing). Additionally, all epochs containing markers (eg, eye open,
eye closed) were rejected because they likely contained artefacts
(signal of no interest). The percentages of epochs removed due
to artefacts in the different groups were the following—control:
6%, aIPD: 10%, sIPD: 20% and sCJD: 29%. We then applied
baseline correction on the artefact-free epochs using the ﬁrst
500 ms of the epoch. We used Independent Component
Analysis (ICA) to remove artefacts that might have been left in
the epochs after the manual rejection. The frequency content of
the epochs between 0 and 128 Hz was computed using fast
Fourier transform (FFT) with steps of 0.33 Hz. After averaging
the result of the FFT analysis across epochs, we deﬁned the
main background frequency as the frequency of the maximum
power between 4 and 15 Hz. We also calculated the total power
within the α (8–12 Hz) and θ (4–7.6 Hz) bands as the area
under the curve and the ratio of α and θ power. Power was
deﬁned as the squared amplitude at each frequency and normal-
ised by dividing it with the average power across trials.
To reduce the dimensionality of the data, we grouped the
electrodes by regions of the scalp. The background frequency
and the power spectrum were not used to deﬁne the regions,
Table 1 Demographic data
n
(excluded) Male
Age in years
(mean±SD) Range
MRC score
at baseline
MMSE at
baseline
Number of
participants with
repeat data (max.
number of repeats)
Time between
first and last
EEG in days
(mean±SD)
Time between
symptom onset
and first EEG in
days (mean±SD)
Controls 29 (2) 17 49.2±12 24–69 20 29.51±0.9 28 (3) 539.0±194.7 NA
Patients 67 (6) 32 47.3±13.7 20–81 17.03±4.7 22.98±8.33 44 (6) 641.0±369.4 NA
Asymptomatic IPD 23 (2) 9 40±13.7 20–72 20 29±1.52 16 (5) 837.8±333.5 NA
Symptomatic IPD 30 (0) 14 46.2±10.2 26–70 16.98±4.13 20.82±8.81 25 (6) 582.8±325.2 1318±1756
sCJD 14 (4) 9 61.8±9.2 44–81 11.18±5.6 16.3±7.7 3 (3) 78±61.4 299±191
The baseline MRC Scale and Mini Mental State Examination (MMSE) scores, the number of participants with more than one EEG recording and the maximum number of EEGs per
participant, the average time between first and last recordings and the time between symptom onset and first EEG are also shown. n: number of participants included in the study. The
number of participants excluded due to high amount of artefacts on the EEG are shown in brackets.
IPD, inherited prion disease; NA, not applicable; sCJD, sporadic Creutzfeldt-Jakob disease.
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they were simply based on topography. We deﬁned the follow-
ing ﬁve groups: frontal left (FL) and frontal right (FR) electro-
des, including FL: Fp1, F3, F7; FR: Fp2, F4, F8; central (Z)
electrodes, including Z: Fz, Cz, Pz; and left (TL) and right
temporo-occipital (TR) electrodes, including TL: C3, P3, T3,
T5, O1; TR: C4, P4, T4, T6, O2 (ﬁgure 1).
The main background frequency, the total power in α and θ
bands and the power ratio were correlated with the MRC Scale
and the MMSE, cross-sectionally and longitudinally. The EEG
parameters of the different participant groups were compared
cross-sectionally, using the last available EEG recording.
Longitudinal analysis was performed using the difference
between the ﬁrst and last EEGs in participants who underwent
more than one recording. When comparing the general relation-
ship between the EEG parameters and the clinical scores, we
included all available measurements from the patients showing
signs of prion disease, namely the sCJD and sIPD groups. The
participants in the control and aIPD group all had maximal
MRC Scale score and normal range MMSE. In the longitudinal
correlation analysis between the EEG parameters and the clin-
ical scores, the difference between the ﬁrst and last measure-
ments from the symptomatic patients was used.
Statistics
We used two-tailed t-test to look for signiﬁcant difference
among the participant groups. To control for the effect of MRC
Scale score in the comparison between sIPD and sCJD patients,
we performed an analysis of covariance with MRC Scale score
as a covariate. A paired t-Test was used to check the difference
between ﬁrst and last EEGs for participants with more than one
EEG recording. Pearson’s correlation was applied to reveal the
relationship between EEG parameters and functional and cogni-
tive scores. The signiﬁcance level was corrected for multiple
comparisons using the Bonferroni correction method.
RESULTS
The comparison between control participants (n=29) and symp-
tomatic patients (sIPD and sCJD; n=44) showed highly signiﬁ-
cant differences in the main background frequency, the θ power
and the α/θ power ratio (ﬁgure 2, table 2 and see online
supplementary table S1).
As expected, the main frequency was lower in patients than in
controls, whereas they had increased power in the θ band and
decreased α/θ power ratio. On the temporo-occipital electrodes,
the α power could also distinguish between these two groups,
being lower in patients than in controls. We next subdivided the
patient group to evaluate whether there were differences among
the patients, namely the sCJD (n=14) and asymptomatic
Figure 1 Location and grouping of electrodes.
Figure 2 Comparison of EEG parameters between healthy participants and patients with prion disease on the ﬁve-electrode groups. Error bars
indicate the SEM. *p<0.0025, **p<0.0001. FL, left frontal; FR, right frontal; TL, left temporal; TR, right temporal electrode group; Z, central.
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(n=23) and symptomatic IPD (n=30) patients (ﬁgure 3). These
comparisons revealed that patients with sCJD showed similar
direction of parameter change as symptomatic IPD; however,
they had signiﬁcantly lower main background frequency, α
power and α/θ power ratio on most of the electrode groups
(except for FL for peak location and FR for α power), consistent
with the more advanced clinical progression of the sCJD group
(see online supplementary table S1 for p values after using
MRC Scale as covariate). The symptomatic IPD patients showed
signiﬁcantly lower main background frequency than the asymp-
tomatic carriers on all the electrode groups. They also had
higher θ power and lower α/θ power ratio all over the scalp.
The α power difference reached signiﬁcant level between the
aIPD and sIPD patients only on the temporal electrode groups.
The asymptomatic IPD patients did not differ signiﬁcantly from
the control group in any of these measurements. For all the sig-
niﬁcance values among patient groups, see online
supplementary table S1.
Further, we examined whether qEEG parameters reﬂect the
differences in the extent of disease progression in patients
(ﬁgure 4). We correlated all available cross-sectional data from
sCJD and symptomatic IPD patients with the MRC Scale score
and the MMSE. We found that the main background frequency
and the α/θ power ratio correlated signiﬁcantly with the MRC
Scale on most of the electrode groups, namely being lower with
worsening score. The α power also reﬂected the worsening on
the left and right temporo-occipital electrodes (table 3).
Signiﬁcant correlation between the MMSE and the main
background frequency was found on the frontal and central
electrodes. Similarly to the MRC Scale, the correlation was posi-
tive, showing lower background frequency in patients with
lower MMSE score. Signiﬁcant positive correlation was found
with the α/θ ratio on the frontal and the right temporo-occipital
electrodes. Correlation coefﬁcients and p values are shown in
table 3 for the MRC Scale and in table 4 for the MMSE and in
online supplementary table S1.
Finally, we found signiﬁcant longitudinal correlation between
change in qEEG parameters and the change in clinical scores
over time (ﬁgure 5). Table 1 details the number of EEGs
Table 2 p Values for the comparisons between the participant
groups for five-electrode groups
Main background
frequency θ power
α/θ power
ratio α power
Controls vs (sIPD+sCJD)
FL 4.4×10−4 2.4×10−7 5.9×10−5 ns
FR ns 1.5×10−7 9.2×10−5 ns
Z 1.6×10−4 8.3×10−10 5.0×10−5 ns
TL 8.6×10−6 3.1×10−10 2.7×10−7 1.3×10−3
TR 3.8×10−6 7.8×10−11 5.1×10−8 1.2×10−3
sIPD vs sCJD
FL ns ns 9.4×10−4 ns
FR 1.2×10−4 ns 1.3×10−3 ns
Z 5.6×10−4 ns ns 1.8×10−3
TL 4.3×10−4 ns 1.5×10−5 1.2×10−5
TR 1.4×10−3 ns 6.6×10−5 4.1×10−5
aIPD vs sIPD
FL 3.6×10−4 1.5×10−3 7.8×10−5 ns
FR 1.1×10−3 1.0×10−3 6.9×10−5 ns
Z 1.1×10−4 9.1×10−6 1.3×10−5 ns
TL 2.3×10−3 3.8×10−7 6.4×10−7 1.0×10−4
TR 3.8×10−4 1.7×10−7 9.4×10−8 1.4×10−4
The significance threshold was adjusted by Bonferroni correction.
FL, left frontal; FR, right frontal; IPD, inherited prion disease; ns, non-significant;
sCJD, sporadic Creutzfeldt-Jakob disease; TL, left temporal; TR, right temporal
electrode group; Z, central.
Figure 3 Comparison of EEG parameters among patients with asymptomatic or symptomatic IPD and sCJD on the ﬁve-electrode groups. Error bars
indicate the SEM. *p<0.0025, **p<0.0001. FL, left frontal; FR, right frontal; IPD, inherited prion disease; sCJD, sporadic Creutzfeldt-Jakob disease;
TL, left temporal; TR, right temporal electrode group; Z, central.
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performed, the time interval and numbers of patients.
Worsening in MRC Scale score correlated signiﬁcantly with the
decrease in the main background frequency on FR (r=0.62,
p=1.5×10−3) but showed a trend, in all the other electrode
groups (p<0.05). A trend of correlation with the decrease in α
power was also observed on the temporal electrodes (p<0.05).
Similarly, the correlation with the MMSE was signiﬁcant on FR
with the main background frequency (r=0.67, p=3.8×10−4)
and on TR with the α/θ ratio (r=0.60, p=2.3×10−3). However,
it showed a trend (p<0.05) on all electrodes with the back-
ground frequency and α/θ ratio, and on the central and
temporo-occipital electrodes with the α power. All p values are
shown in online supplementary table S1.
DISCUSSION
We aimed to develop qEEG biomarkers of disease progression
in prion diseases with potential utility in an experimental
medical setting. There are a number of reasons to expect prion
diseases to be peculiarly appropriate for this technology.
Pathological features of prion disease are widespread throughout
the cerebral cortex, subcortical nuclei, brainstem and cerebel-
lum, meaning that biomarkers of brain structure are unlikely to
be as useful as they are in neurodegenerative diseases associated
with focal atrophy. Furthermore, EEG PSWCs have long been
recognised as a marked neurophysiological feature and
incorporated into epidemiological diagnostic criteria. However,
these characteristic waves are more frequent in certain types of
sCJD (MM1 and MV1)9 20 patients, whereas they rarely occur
in VV2 and MV2 types.9 21 Our goal was to develop a bio-
marker that is representative of all types of prion diseases (the
different sCJD subtypes and the inherited forms). To this end,
we used for the ﬁrst time qEEG analysis and evaluated the dif-
ference in qEEG parameters between patients with different
forms of prion diseases and healthy controls.
Our analyses revealed highly signiﬁcant decreases in the main
background frequency, α power and α/θ power ratio and signiﬁ-
cant increase in θ power in patients compared to healthy partici-
pants. These ﬁndings are in accordance with studies comparing
patients with Alzheimer’s disease, mild cognitive impairment
and healthy elderly controls.16 22–24 Similarly, patients with
Parkinson’s disease and cognitive decline have increased θ and
decreased α power and signiﬁcantly lower median frequency
compared to healthy controls.25 26 When subdividing the
patient group, we found lower background frequency, α power
and α/θ power ratio in patients with sCJD when compared to
the IPD group, in parallel to differences in the MRC Scale
scores. Asymptomatic carriers of prion protein gene mutation
did not show any EEG abnormalities.
To evaluate these EEG differences as potential progression
biomarkers, we correlated the derived EEG parameters with the
Figure 4 Correlation between the main background frequency and the MRC Scale (A)/ Mini Mental State Examination (MMSE) (B) scores for the
symptomatic patients (sIPD and sCJD) with the 95% CI on the right frontal electrode group. FR, right frontal.
Table 3 Correlation coefficients (r) and p values for the significant
correlations between MRC Scale and EEG parameters
MRC Scale
Main background
frequency α/θ power ratio α power
r p Value r p Value r p Value
FL 0.39 9.0×10−5 0.33 1.1×10−3 0.29 ns
FR 0.40 5.7×10−5 0.31 2.1×10−3 0.28 ns
Z 0.35 4.3×10−4 0.26 ns 0.28 ns
TL 0.37 2.4×10−4 0.35 3.9×10−4 0.42 1.7×10−5
TR 0.43 1.3×10−5 0.34 6.6×10−4 0.41 3.6×10−5
The significance threshold was adjusted by Bonferroni correction.
FL, left frontal; FR, right frontal; ns, non-significant; TL, left temporal; TR, right
temporal electrode group; Z, central.
Table 4 Correlation coefficients (r) and p values for the significant
correlations between MMSE and EEG parameters
MMSE
Main background
frequency α/θ power ratio α power
r p Value r p Value r p Value
FL 0.37 2.0×10−4 0.35 4.2×10−4 0.24 ns
FR 0.36 2.8×10−4 0.34 7.7×10−4 0.25 ns
Z 0.32 1.4×10−3 0.26 ns 0.20 ns
TL 0.25 ns 0.28 ns 0.22 ns
TR 0.29 ns 0.31 1.6×10−3 0.25 ns
The significance threshold was adjusted by Bonferroni correction.
FL, left frontal; FR, right frontal; MMSE, Mini Mental State Examination;
ns, non-significant; TL, left temporal; TR, right temporal electrode group; Z, central.
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clinical and cognitive scores. We found that the main back-
ground frequency and the α/θ power ratio correlated signiﬁ-
cantly with the MRC Scale score and MMSE; namely that
patients with lower clinical and cognitive scores had lower main
frequency and α/θ power ratio. We also found signiﬁcant correl-
ation between the α power and the MRC Scale score. Similarly
to our ﬁndings, previous studies have also described lower peak
frequency and lower α activity during memory tasks in patients
with Alzheimer’s disease who had decreased MMSE or Global
Deterioration Scale scores or decline on the Cambridge
Cognitive Examination.17 24 27 28 Besides the signiﬁcant correl-
ation in the cross-sectional data, we found that the decrease in
main background frequency over time also showed correlation
with the functional and cognitive decline in prion patients. The
α power and α/θ power ratio also decreased with decrease in
MRC and MMSE scores. Similarly to our ﬁndings, others have
reported reduced α power after 1-year follow-up in patients
with progressive mild cognitive impairment and Alzheimer’s
disease when compared to those with stable mild cognitive
impairment.29 Another longitudinal study examining patients
with Parkinson’s disease and cognitive decline showed signiﬁ-
cant correlation between the increase in delta power and the
reduction in MMSE score. Even though the change in back-
ground frequency, θ and α power did not show correlation with
the decrease in MMSE in their study, a more sensitive neuro-
psychological test (Auditory Verbal Learning Test) correlated sig-
niﬁcantly with the change in background frequency.30
Our studies of a rare disease are necessarily limited by sample
size. In the longitudinal analysis, we had less data than in the
cross-sectional tests, because we could only include those parti-
cipants who had at least two good-quality EEGs. The smaller
sample size, therefore, be responsible for variability in the esti-
mated correlations between the EEG parameters and the func-
tional and cognitive scores. Nevertheless, the strong effects we
detected show that these EEG measurements are able to reﬂect
the progression of the disease within patients with prion dis-
eases. Taken together with the case–control ﬁndings, these data
suggest that the predictive or longitudinal changes in qEEG
parameters might be a shared consequence of neurodegenera-
tion in different types of dementias.
Artefacts decreased the quality of many EEG recordings and
resulted in removal of part or the entire recording. The most
common type of artefacts was due to eye movements. This
included blinks and the movements of the eyeballs. Parts of the
EEG recording containing any eye movement artefacts were
rejected either automatically by independent component analysis
or manually after inspection. Recording the electro-oculogram,
which was not possible in the current study, would make the
removal of these artefacts more precise in the future.
Drowsiness and sleep during the EEG recording also resulted in
rejection of part of the data. The normal decrease in back-
ground frequency during sleep could mimic the abnormal
decrease in the main frequency, which is the result of the
disease. Therefore, all parts of the recordings that showed signs
of sleep I or II stages were manually rejected. Avoiding the parti-
cipants sleeping by intermittent interaction during the recording
could reduce this type of artefact. A small proportion of data
had to be rejected because of high-frequency artefact or low-
amplitude signal that could not be eliminated during the record-
ing session.
The current study was also limited by the relatively small
number of sCJD patients. At present in the UK, sCJD is often
diagnosed late in the clinical course when patients are too unwell
to travel for research neurophysiological studies. It was also difﬁ-
cult to record more than one EEG in sCJD because of the rapid
progression of the disease. The use of different recording systems
and different ﬁle types made difﬁcult to use EEGs recorded from
other hospitals, and we therefore decided to focus on the most
homogeneous subset recorded at NHNN. If the qEEG para-
meters we report here were to be used in an exploratory fashion
to provide supportive evidence for alteration in the natural
history of sCJD in trials of experimental therapeutics, then enrol-
ment rates would likely be substantially higher.
We did not ﬁnd any differences between qEEG parameters in
asymptomatic gene mutation carriers compared with healthy
controls. Two interpretations are plausible: (1) the EEG does
become abnormal several years before clinical onset, reﬂecting
incipient neurodegeneration, but there were too few patients
close to actual clinical onset in the aIPD group to detect this and
(2) the EEG only becomes abnormal in IPD at clinical onset.
Continued follow-up of aIPD patients and retrospective analysis
of converting clinical cases may be helpful.
In conclusion, we found strong correlations between several
qEEG parameters and prion disease diagnosis, severity and
Figure 5 Correlation between the change in main background frequency and the change in MRC Scale (A)/Mini Mental State Examination (MMSE)
(B) scores over time for the symptomatic patients (sIPD and sCJD) with the 95% CI on the right frontal electrode group. FR, right frontal.
6 Franko E, et al. J Neurol Neurosurg Psychiatry 2016;0:1–7. doi:10.1136/jnnp-2016-313501
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progression over time. Priorities for future work include the
use of these technologies in a clinical trial setting as an
exploratory biomarker, the continued study of healthy at-risk
individuals and consideration of related technologies such as
magnetoencephalography.
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the progression of human prion diseases
Quantitative EEG parameters correlate with
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